SLK-Kliniken GmbH - Standort Fachklinik Löwenstein
- Address
- lock Available on a paid plan
SLK-Kliniken GmbH - Fachklinik Löwenstein: Specialized Thoracic Oncology Research
The Fachklinik Löwenstein, part of SLK-Kliniken GmbH, is a specialized medical facility dedicated to advancing treatment approaches for non-small cell lung cancer (NSCLC). The center demonstrates particular expertise in investigating novel therapeutic strategies across different stages of lung cancer, from resectable tumors to locally advanced disease, with a strong focus on immunotherapy-based treatment regimens.
- Immunotherapy combinations for untreated locally advanced NSCLC using checkpoint inhibitors
- Neoadjuvant and adjuvant treatment protocols for resectable non-small cell lung cancer
- Novel antibody-drug conjugate therapies combined with immunological agents
The research program emphasizes precision oncology approaches evaluating both established immunotherapy agents like nivolumab and ipilimumab, as well as innovative combinations such as sacituzumab govitecan with zimberelimab. Through participation in multicenter phase II and comparative trials, the facility contributes to determining optimal sequencing of perioperative therapies and identifying biomarkers for treatment response, with primary endpoints including progression-free survival and pathological complete response rates.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in SLK-Kliniken GmbH - Standort Fachklinik Löwenstein
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Phase 3 Randomized Study of Nivolumab and Ipilimumab with Chemoradiotherapy in Locally Advanced Non-Small Cell Lung Cancer | Bristol Myers Squibb International Corporation | Phase III | Not Recruiting | Nov 2019 | Mar 2024 |
IMP list
lock Showing 1 of 11 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Carboplatin | 1 | Unknown | 2019-11-20 | 2019-11-20 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.